The Case CCC Imaging Research Core Facility provides researchers with state-of-the art facilities and the services for in vivo imaging. The facility provides cancer researchers its extensive imaging research infrastructure and expertise of -26 imaging faculty in Radiology, Chemistry, Physics, and Biomedical Engineering to enhance and expand ongoing research efforts. The advent of dedicated small animal imaging systems allows the integration of in vivo physiologic measurements with microscopic measurements of structural and cellular activities. The collaborative, multidisciplinary approach provides a wealth of new information in elucidating the complex relationship between structure, genetics, replication, and function in genetically manipulated animal models of disease that have been used widely in cancer research with grounding in cellular/molecular-level understanding. The Imaging Research Core Facility is the centerpiece of the Case Center for Imaging Research, which encompasses all aspects of the much broader imaging research program at Case/UH. This includes molecular imaging, small animal imaging, and clinical imaging thrusts. The Core provides services to Case CCC members from 7 of 8 research programs, with members from the Imaging Program and Cancer Cell Signaling utilizing the Core's services the most. The Core has been actively involved in studies of the glioma microenvironment where novel cryo-imaging techniques demonstrated migration and dispersal pathways in vivid three-dimensional detail. In addition, fluorescence imaging systems in the Core were used to discover that while activation of EphA2 with its ligand ephrin-AI inhibits chemotactic migration of glioma and prostate cancer cells, EphA2 over-expression promotes migration in a ligand-independent manner.
The Case Comprehensive Cancer Center is Northeast Ohio's only NCI designated comprehensive cancer center providing bench-to-bedside medical research involving partnerships between basic, clinical and population scientists to speed translation of laboratory discoveries into new prevention/intervention and cancer treatments.
|Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18|
|Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578|
|Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464|
|Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726|
|He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135|
|Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:|
|Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173|
|Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414|
|Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143|
|Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279|
Showing the most recent 10 out of 1227 publications